Forma Therapeutics Holdings's gross profit is $0, below the Healthcare sector average of $67B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2022
Trailing 12 months ending Jun 30, 2022
Forma Therapeutics Holdings posts a gross profit of $0 as of June 2022. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $67B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Forma Therapeutics Holdings's gross profit was $0. The latest reading is $0 (period ending June 2022). Use the history and growth charts on this page for a longer lookback.
For Healthcare stocks, a gross profit near $67B is typical. Forma Therapeutics Holdings's $0 is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Gross Profit is one piece of Forma Therapeutics Holdings's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for FMTX's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $67B), and (3) consistency with growth and profitability. This page covers the first two; Forma Therapeutics Holdings's other metric pages and overview cover the third.